Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPERNOVA
NCT05648110Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of sipavibart and AZD5156 in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by AstraZeneca. Primary endpoints: Occurrence of Adverse Events, Occurrence of Serious Adverse Events, Medically Attended Adverse Events, and Adverse Events of Special Interest at Day 461 and 2 more. Started Dec 2022; status: completed.
02
Drugs
sipavibartAZD5156
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05648110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648110.